<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203774</url>
  </required_header>
  <id_info>
    <org_study_id>10-0788</org_study_id>
    <nct_id>NCT01203774</nct_id>
  </id_info>
  <brief_title>Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital</brief_title>
  <official_title>&quot;Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients Discharged From the Hospital&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators would like to test the hypothesis that in diabetic patients&#xD;
      discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected&#xD;
      Glargine in terms of diabetes control, compliance, and patient satisfaction and preference.&#xD;
      The investigators will test this hypothesis in a randomized, crossover trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c at Three Months of Each Period of Treatment</measure>
    <time_frame>Baseline, Month 3 (End of Intervention 1), Month 6 (End of intervention 2)</time_frame>
    <description>Data was collected by group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance and Patient Satisfaction</measure>
    <time_frame>6 months of treatment after discharge from the hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Pen-administered vs syringe-admnistered Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Syringe-administered vs pen-administered Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Syringe-administered Glargine insulin and then pen-administered Glargine insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine insulin</intervention_name>
    <description>20-180 units per day</description>
    <arm_group_label>Pen-administered vs syringe-admnistered Glargine</arm_group_label>
    <arm_group_label>Syringe-administered vs pen-administered Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with type 1 and 2 diabetes discharged from the hospital with&#xD;
             recommendations to take Glargine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to participate and patients incapable of complying with the study&#xD;
             regimen, such as patients with alcohol and drug addiction problems and patients with&#xD;
             severe mental illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Draznin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>July 15, 2021</results_first_submitted>
  <results_first_submitted_qc>July 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2021</results_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although this is a crossover study, no information is available on the participants that completed phase 1 and started phase 2, and so these milestones are not included. Multiple attempts were made to obtain this information, however the PI is retired and data could not be obtained from any remaining personnel associated with the study. The number of participants started and completed reflects the participants confirmed to have started and completed the study. 43 participants were consented.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pen-administered, Then Syringe-admnistered Glargine</title>
          <description>SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
        </group>
        <group group_id="P2">
          <title>Syringe-administered Then Pen-administered Glargine</title>
          <description>Syringe-administered Glargine insulin and then pen-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants are grouped into a single arm because no demographics information regarding the separate arms exists. Consented participants that did not complete the study cannot be excluded. Multiple attempts were made to obtain more precise data, however the PI has retired and neither he nor any members of the study team or other contacts associated with the study were able to locate the data.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Pen-administered, then syringe-admnistered Glargine Group (1) AND Syringe-administered then pen-administered Glargine Group (2)&#xD;
Group 1: SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin Glargine insulin: 20-180 units per day&#xD;
Group 2: Syringe-administered Glargine insulin and then pen-administered Glargine insulin Glargine insulin: 20-180 units per day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 22-70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c at Three Months of Each Period of Treatment</title>
        <description>Data was collected by group</description>
        <time_frame>Baseline, Month 3 (End of Intervention 1), Month 6 (End of intervention 2)</time_frame>
        <population>The only outcome measure available for this measurement is &quot;by group&quot;. This measure cannot be entered &quot;by intervention&quot; (e.g. Arm 1: &quot;Pen&quot;, Arm 2: &quot;Syringe&quot;). Multiple attempts were made to obtain this information, however the PI is retired and data could not be obtained from any remaining personnel associated with the study. Participants that did not complete the study are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Pen-administered, Then Syringe-admnistered Glargine</title>
            <description>SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Syringe-administered Then Pen-administered Glargine</title>
            <description>Syringe-administered Glargine insulin and then pen-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c at Three Months of Each Period of Treatment</title>
          <description>Data was collected by group</description>
          <population>The only outcome measure available for this measurement is &quot;by group&quot;. This measure cannot be entered &quot;by intervention&quot; (e.g. Arm 1: &quot;Pen&quot;, Arm 2: &quot;Syringe&quot;). Multiple attempts were made to obtain this information, however the PI is retired and data could not be obtained from any remaining personnel associated with the study. Participants that did not complete the study are not included.</population>
          <units>percentage (DCCT unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="2.2"/>
                    <measurement group_id="O2" value="11.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1C at 3 months (end of intervention 1, before crossover)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.7"/>
                    <measurement group_id="O2" value="7.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c at 6 Months (end of dose 2, after crossover)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.0"/>
                    <measurement group_id="O2" value="7.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance and Patient Satisfaction</title>
        <time_frame>6 months of treatment after discharge from the hospital</time_frame>
        <population>No data is available for this outcome measure. Multiple attempts were made to obtain this information, however the PI is retired and data could not be obtained from any remaining personnel associated with the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Pen-administered, Then Syringe-admnistered Glargine</title>
            <description>SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Syringe-administered Then Pen-administered Glargine</title>
            <description>Syringe-administered Glargine insulin and then pen-administered Glargine insulin&#xD;
Glargine insulin: 20-180 units per day</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance and Patient Satisfaction</title>
          <population>No data is available for this outcome measure. Multiple attempts were made to obtain this information, however the PI is retired and data could not be obtained from any remaining personnel associated with the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pen-administered Glargine</title>
          <description>Glargine insulin: 20-180 units per day</description>
        </group>
        <group group_id="E2">
          <title>Syringe-administered Glargine</title>
          <description>Glargine insulin: 20-180 units per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited results information is available. Multiple attempts were made to obtain this information, however the PI is retired and additional data could not be obtained from any remaining personnel associated with the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Administration</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>3037241111</phone>
      <email>clinicalresearchsupportcenter@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

